ClinicalTrials.gg
CompletedNCT04588298SERENA-3Updated Jan 24, 2025Results posted

A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer

A Phase 2 interventional study of AZD9833 in HER2-negative Breast Cancer, sponsored by AstraZeneca. Completed at 12 sites in 3 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing AZD9833 in Breast Neoplasms — 6 open to participants now, 10 under way, 7 of them phase 3. AZD9833 · Breast Neoplasms.

Enrollment
10th of 17
135 · median 150
Started
2020
with 2 others
Phase 2
3 of 17
2 open now
Registered
3rd of 17
by date
Lead sponsor
15 of 17
AstraZeneca

Among the 17 studies testing AZD9833 in Breast Neoplasms, this one is the 10th largest by enrollment, is one of 3 that started in 2020, is one of 3 in phase 2, and was the 3rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 17 studies testing AZD9833 in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About AZD9833

AZD9833: first FDA approval 2026 (ETCAMAH), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing AZD9833 in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a randomised, open-label, parallel-group, pre-surgical study aimed to investigate the biological effects, safety, tolerability, and pharmacokinetics (PK) of different doses of oral AZD9833 in post-menopausal women with primary breast cancer

Read the detailed description

The study will be conducted in approximately 20 study centers across 3 countries and will be conducted in three stages (stage 1, stage 2 and stage 3). After the screening visit and confirmation of eligibility, evaluable participants will be enrolled across treatment groups. In stage 1, up to 24 evaluable participants across two treatment groups will be enrolled. A Safety and Data Monitoring Committee will convene to review stage 1 data and decide whether further treatment groups are required in stage 2. Stage 2 will include participants across up to 3 treatment groups. Stage 3 will include two treatment groups:

Stage 1 Group 1: AZD9833 Dose A once daily Group 2: AZD9833 Dose B once daily

Stage 2 Group 1: AZD9833 Dose A once daily Group 2: AZD9833 Dose B once daily Group 3: AZD9833 Dose C once daily

Stage 3 Group 1: AZD9833 Dose A once daily Group 2: AZD9833 Dose B once daily

Adverse events and concomitant medications information will be collected throughout the study. Thereafter there will be 28-day follow-up visit after discontinuation of study treatment

03

Conditions studied

  • HER2-negative Breast Cancer

Browse trials for

Keywords

  • Breast cancer
  • Breast carcinoma
  • Estrogen-Receptor-positive breast cancer
  • HER2-negative breast cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of written prior to study entry
  • Female participants aged at least 18 years
  • status defined as meeting at least one of the following criteria:

    1. Have undergone a bilateral oophorectomy
    2. Age ≥ 60 years
    3. Age ≥ 50 and \< 60 years and with cessation of menses ≥ 12 months and follicle-stimulating hormone and oestradiol levels in the post-menopausal range and with an intact uterus in the absence of oral or hormone replacement therapy prior to the diagnosis of breast cancer
  • Female participants with newly diagnosed primary breast cancer scheduled to undergo treatment with curative intent by surgery and irrespective of clinical node status
  • confirmed invasive breast cancer involving a palpable tumour of any size, or a tumour with an ultrasound assessed diameter of ≥ 1.0 cm
  • Participants with adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥ 3 months can be considered for the study
  • According to the local laboratory participants must have:

    1. ER positive breast cancer
    2. -negative breast cancer
  • (ECOG) performance status 0 to 1

Exclusion criteria

Exclusion Criteria:

  • Previous systemic or local treatment for the new primary breast cancer currently under investigation (including surgery, radiotherapy, cytotoxic and endocrine treatments)
  • Intervention with any of the following:

    1. Use of sex-hormone-containing drugs within 6 months prior to the first dose of study treatment
    2. Medications or herbal supplements known to be strong inhibitors/inducers of /5, sensitive CYP2B6 substrates and drugs which are substrates of CYP2C9 and/or CYP2C19 which have a narrow therapeutic index
    3. Drugs that are known to prolong and have a known risk of torsades de pointes
  • Inflammatory breast cancer
  • Any evidence of severe or uncontrolled systemic diseases which in the investigator's opinion makes it undesirable for the participant to participate in the study
  • Any of the following cardiovascular criteria: Mean resting QTcF > 470 msec; resting heart rate of \< 50 bpm for stages 1 and 2 at screening;resting heart rate \<60 bpm at screening for Stage 3; any abnormalities in rhythm, conduction, or morphology of resting ; any factors that increase the risk of QTc prolongation or risk of arrhythmic events; known \< 50%; significant cardiovascular procedure or event within the last 6 months; uncontrolled hypertension or symptomatic hypotension
  • Inadequate bone marrow reserve or organ function
  • nausea and vomiting, uncontrolled chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9833
  • History of to active or inactive of AZD9833
  • Previous randomisation in the present study
  • Judgement by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Stage 1: AZD9833 Dose A

    Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 1 of the study.

    Drug: AZD9833

  • Experimental
    Stage 1: AZD9833 Dose B

    Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 1 of the study.

    Drug: AZD9833

  • Experimental
    Stage 2: AZD9833 Dose A

    Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 2 of the study.

    Drug: AZD9833

  • Experimental
    Stage 2: AZD9833 Dose B

    Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 2 of the study.

    Drug: AZD9833

  • Experimental
    Stage 2: AZD9833 Dose C

    Post-menopausal participants will receive once daily oral dose C of AZD9833 in stage 2 of the study.

    Drug: AZD9833

  • Experimental
    Stage 3: AZD9833 Dose A

    Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 3 of the study.

    Drug: AZD9833

  • Experimental
    Stage 3: AZD9833: Dose B

    Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 3 of the study.

    Drug: AZD9833

Interventions

  • AZD9833 tablets will be administered orally.

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis)

    The pharmacodynamic (PD) effect of AZD9833 on ER expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by immunohistochemistry (IHC) method. The percentage change was calculated from an analysis of covariance (ANCVOA) model adjusting for baseline ER score and day of on-treatment biopsy.

    Time frame: Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])

  2. Percentage Change From Baseline in ER Expression Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis)

    The PD effect of AZD9833 on ER expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The sensitivity analysis excluded any patients who were HER2-positive patient by central assessment as well as patients with baseline ER H-score \< 10. The percentage change was calculated from ANCVOA model adjusting for baseline ER score and day of on-treatment biopsy.

    Time frame: Baseline (Screening Day -21 to 1) to Biopsy Day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])

Secondary outcomes

  1. Percentage Change From Baseline in Progesterone Receptor (PgR) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis)

    The PD effects of AZD9833 on PgR expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The percentage change was calculated from an ANCOVA model adjusting for baseline PgR score and day of on-treatment biopsy.

    Time frame: Baseline (Screening Day -21 to 1) to Biopsy Day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])

  2. Percentage Change From Baseline in PgR Expression Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis)

    The PD effects of AZD9833 on PgR expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The sensitivity analysis excluded any patients who were HER2-positive patient by central assessment as well as patients with baseline PgR H-score \< 10. The percentage change was calculated from an ANCOVA model adjusting for baseline PgR score and day of on-treatment biopsy.

    Time frame: Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])

  3. Percentage Change From Baseline in Ki-67 Labelling Index Between Pre- and On-treatment Tumour Samples (Primary Analysis)

    The PD effect of AZD9833 on antigen Ki-67 expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The percentage change was calculated from an ANCOVA model adjusting for log baseline Ki67 index and day of on-treatment biopsy. The Ki-67 index data were log transformed prior to analysis, with results back-transformed to represent percentage change.

    Time frame: Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])

  4. Percentage Change From Baseline in Ki-67 Labelling Index Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis)

    The PD effect of AZD9833 on antigen Ki-67 expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The sensitivity analysis excluded any patients who were HER2-positive patient by central assessment as well as patients with baseline Ki67 labelling index \<5%. The percentage change was calculated from an ANCOVA model adjusting for log baseline Ki67 index and day of on-treatment biopsy. The Ki-67 index data were log transformed prior to analysis, with results back-transformed to represent percentage change.

    Time frame: Baseline (Screening Day -21 to 1) to Biopsy Day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])

  5. Number of Patients With Adverse Events (AEs)

    The safety and tolerability of AZD9833 in this patient population was evaluated.

    Time frame: From screening (Day -21 to 1) through 28-day follow-up (Upto 2 months)

  6. Plasma Concentrations of AZD9833

    The plasma concentration of AZD9833 in this participant population was evaluated

    Time frame: Days 5-7 or Days 12-15 (Pre and Post biopsy)

07

Results

Posted Jan 24, 2025

Participant flow

The study was conducted at 13 sites in 3 countries between November 2, 2020 and June 19, 2023.

Participant flow — Overall Study
MilestoneAZD9833 75 mg (Stage 1 + 2)AZD9833 150 mg (Stage 1 + 2)AZD9833 300 mg (Stage 2)AZD9833 75 mg (Stage 3)AZD9833 150 mg (Stage 3)
Started3033133029
Completed2933122927
Not completed10112
Withdrew: Adverse event00102
Withdrew: Withdrawal by subject10010

Outcome measures

PrimaryPercentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis)

The pharmacodynamic (PD) effect of AZD9833 on ER expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by immunohistochemistry (IHC) method. The percentage change was calculated from an analysis of covariance (ANCVOA) model adjusting for baseline ER score and day of on-treatment biopsy.

Time frame:
Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])
Reported as:
Least squares mean · Percentage change from baseline
Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis)
Percentage change from baselineAZD9833 75 mg (Stage 1 + 2)AZD9833 150 mg (Stage 1 + 2)AZD9833 300 mg (Stage 2)AZD9833 75 mg (Stage 3)AZD9833 150 mg (Stage 3)
Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis)-62.7 (-67.46 to -57.93)-62.8 (-67.13 to -58.43)-67.1 (-74.49 to -59.74)-66.9 (-72.34 to -61.46)-65.0 (-70.27 to -59.81)
PrimaryPercentage Change From Baseline in ER Expression Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis)

The PD effect of AZD9833 on ER expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The sensitivity analysis excluded any patients who were HER2-positive patient by central assessment as well as patients with baseline ER H-score \< 10. The percentage change was calculated from ANCVOA model adjusting for baseline ER score and day of on-treatment biopsy.

Time frame:
Baseline (Screening Day -21 to 1) to Biopsy Day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])
Reported as:
Least squares mean · Percentage change from baseline
Percentage Change From Baseline in ER Expression Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis)
Percentage change from baselineAZD9833 75 mg (Stage 1 + 2)AZD9833 150 mg (Stage 1 + 2)AZD9833 300 mg (Stage 2)AZD9833 75 mg (Stage 3)AZD9833 150 mg (Stage 3)
Percentage Change From Baseline in ER Expression Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis)-62.1 (-67.00 to -57.25)-62.3 (-66.64 to -57.88)-66.6 (-74.00 to -59.14)-66.9 (-72.34 to -61.46)-65.0 (-70.27 to -59.81)
SecondaryPercentage Change From Baseline in Progesterone Receptor (PgR) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis)

The PD effects of AZD9833 on PgR expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The percentage change was calculated from an ANCOVA model adjusting for baseline PgR score and day of on-treatment biopsy.

Time frame:
Baseline (Screening Day -21 to 1) to Biopsy Day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])
Reported as:
Least squares mean · Percentage change from baseline
Percentage Change From Baseline in Progesterone Receptor (PgR) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis)
Percentage change from baselineAZD9833 75 mg (Stage 1 + 2)AZD9833 150 mg (Stage 1 + 2)AZD9833 300 mg (Stage 2)AZD9833 75 mg (Stage 3)AZD9833 150 mg (Stage 3)
Percentage Change From Baseline in Progesterone Receptor (PgR) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis)194.8 (25.50 to 364.03)-3.0 (-158.37 to 152.36)170.3 (-89.67 to 430.33)-24.2 (-547.03 to 498.69)463.8 (-38.45 to 966.02)
SecondaryPercentage Change From Baseline in PgR Expression Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis)

The PD effects of AZD9833 on PgR expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The sensitivity analysis excluded any patients who were HER2-positive patient by central assessment as well as patients with baseline PgR H-score \< 10. The percentage change was calculated from an ANCOVA model adjusting for baseline PgR score and day of on-treatment biopsy.

Time frame:
Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])
Reported as:
Least squares mean · Percentage change from baseline
Percentage Change From Baseline in PgR Expression Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis)
Percentage change from baselineAZD9833 75 mg (Stage 1 + 2)AZD9833 150 mg (Stage 1 + 2)AZD9833 300 mg (Stage 2)AZD9833 75 mg (Stage 3)AZD9833 150 mg (Stage 3)
Percentage Change From Baseline in PgR Expression Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis)-35.2 (-45.86 to -24.57)-44.0 (-53.09 to -34.90)-36.7 (-52.96 to -20.52)-61.8 (-76.93 to -46.62)-55.0 (-71.29 to -38.78)
SecondaryPercentage Change From Baseline in Ki-67 Labelling Index Between Pre- and On-treatment Tumour Samples (Primary Analysis)

The PD effect of AZD9833 on antigen Ki-67 expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The percentage change was calculated from an ANCOVA model adjusting for log baseline Ki67 index and day of on-treatment biopsy. The Ki-67 index data were log transformed prior to analysis, with results back-transformed to represent percentage change.

Time frame:
Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])
Reported as:
Geometric least squares mean · Percentage change from baseline
Percentage Change From Baseline in Ki-67 Labelling Index Between Pre- and On-treatment Tumour Samples (Primary Analysis)
Percentage change from baselineAZD9833 75 mg (Stage 1 + 2)AZD9833 150 mg (Stage 1 + 2)AZD9833 300 mg (Stage 2)AZD9833 75 mg (Stage 3)AZD9833 150 mg (Stage 3)
Percentage Change From Baseline in Ki-67 Labelling Index Between Pre- and On-treatment Tumour Samples (Primary Analysis)-40.3 (-52.78 to -24.49)-79.4 (-83.37 to -74.55)-78.2 (-84.82 to -68.77)-73.0 (-79.42 to -64.64)-77.5 (-82.68 to -70.86)
SecondaryPercentage Change From Baseline in Ki-67 Labelling Index Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis)

The PD effect of AZD9833 on antigen Ki-67 expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The sensitivity analysis excluded any patients who were HER2-positive patient by central assessment as well as patients with baseline Ki67 labelling index \<5%. The percentage change was calculated from an ANCOVA model adjusting for log baseline Ki67 index and day of on-treatment biopsy. The Ki-67 index data were log transformed prior to analysis, with results back-transformed to represent percentage change.

Time frame:
Baseline (Screening Day -21 to 1) to Biopsy Day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])
Reported as:
Geometric least squares mean · Percentage change from baseline
Percentage Change From Baseline in Ki-67 Labelling Index Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis)
Percentage change from baselineAZD9833 75 mg (Stage 1 + 2)AZD9833 150 mg (Stage 1 + 2)AZD9833 300 mg (Stage 2)AZD9833 75 mg (Stage 3)AZD9833 150 mg (Stage 3)
Percentage Change From Baseline in Ki-67 Labelling Index Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis)-49.3 (-62.18 to -31.96)-81.3 (-85.14 to -76.49)-78.9 (-85.37 to -69.46)-81.7 (-86.45 to -75.24)-81.9 (-86.38 to -75.88)
SecondaryNumber of Patients With Adverse Events (AEs)

The safety and tolerability of AZD9833 in this patient population was evaluated.

Time frame:
From screening (Day -21 to 1) through 28-day follow-up (Upto 2 months)
Reported as:
Count of participants · Participants
Number of Patients With Adverse Events (AEs)
ParticipantsAZD9833 75 mg (Stage 1 + 2)AZD9833 150 mg (Stage 1 + 2)AZD9833 300 mg (Stage 2)AZD9833 75 mg (Stage 3)AZD9833 150 mg (Stage 3)
Any AE91791119
Any AE possibly related to treatment41461017
Any AE of CTCAE grade 3 or higher01000
Any AE of CTCAE grade 3 or higher, possibly related to treatment01000
Any AE with outcome = death00000
Any AE with outcome = death, possibly related to treatment00000
Any SAE (including events with outcome = death)00000
Any SAE (including events with outcome = death), possibly related to treatment00000
Any SAE leading to discontinuation of treatment00000
Any SAE leading to discontinuation of treatment, possibly related to treatment00000
Any AE leading to discontinuation of treatment00102
Any AE leading to discontinuation of treatment, possibly related to treatment00002
Any AE leading to dose modification of treatment00000
Any AE leading to dose modification of treatment, possibly related to treatment00000
Any other significant AEs00000
SecondaryPlasma Concentrations of AZD9833

The plasma concentration of AZD9833 in this participant population was evaluated

Time frame:
Days 5-7 or Days 12-15 (Pre and Post biopsy)
Reported as:
Geometric mean · Nanograms per milliliter
Plasma Concentrations of AZD9833
Nanograms per milliliterAZD9833 75 mg (Stage 1 + 2)AZD9833 150 mg (Stage 1 + 2)AZD9833 300 mg (Stage 2)AZD9833 75 mg (Stage 3)AZD9833 150 mg (Stage 3)
Days 5-7 or Days 12-15 (Pre-biopsy)50.712 ± 74.1122.134 ± 103.8180.773 ± 173.346.939 ± 56.3120.516 ± 70.0
Days 5-7 or Days 12-15 (Post-biopsy)58.304 ± 62.2142.916 ± 102.4213.446 ± 175.654.075 ± 42.8137.687 ± 55.4

Adverse events

Collected over From screening (Day -21 to 1) through 28-day follow-up (Up to 2 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD9833 75 mg (Stage 1 + 2)0/30 (0%)0/30 (0%)7/30 (23.3%)
AZD9833 150 mg (Stage 1 + 2)0/33 (0%)0/33 (0%)17/33 (51.5%)
AZD9833 300 mg (Stage 2)0/13 (0%)0/13 (0%)9/13 (69.2%)
AZD9833 75 mg (Stage 3)0/30 (0%)0/30 (0%)11/30 (36.7%)
AZD9833 150 mg (Stage 3)0/29 (0%)0/29 (0%)19/29 (65.5%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventAZD9833 75 mg (Stage 1 + 2)AZD9833 150 mg (Stage 1 + 2)AZD9833 300 mg (Stage 2)AZD9833 75 mg (Stage 3)AZD9833 150 mg (Stage 3)
Visual impairmentEye disorders0/305/333/136/307/29
HypertensionVascular disorders1/302/333/131/304/29
DiplopiaEye disorders0/304/331/130/305/29
PhotopsiaEye disorders2/304/332/133/304/29
NauseaGastrointestinal disorders4/303/331/132/301/29
HeadacheNervous system disorders2/303/331/133/303/29
DizzinessNervous system disorders0/302/331/132/303/29
Sinus bradycardiaCardiac disorders0/300/330/130/303/29
FatigueGeneral disorders2/303/330/130/300/29
COVID-19Infections and infestations0/300/331/130/300/29

Baseline characteristics

Safety Analysis Set was defined as all patients who received any amount of study treatment, regardless of whether that was the randomized therapy intended.

Age, Continuous
Age, Continuous(Years)AZD9833 75 mg (Stage 1 + 2)AZD9833 150 mg (Stage 1 + 2)AZD9833 300 mg (Stage 2)AZD9833 75 mg (Stage 3)AZD9833 150 mg (Stage 3)Total
Mean62.0 ± 7.3565.7 ± 7.5366.3 ± 8.2064.0 ± 8.6567.2 ± 10.0364.9 ± 8.49
Sex: Female, Male
Sex: Female, Male(Participants)AZD9833 75 mg (Stage 1 + 2)AZD9833 150 mg (Stage 1 + 2)AZD9833 300 mg (Stage 2)AZD9833 75 mg (Stage 3)AZD9833 150 mg (Stage 3)Total
Female3033133029135
Male000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AZD9833 75 mg (Stage 1 + 2)AZD9833 150 mg (Stage 1 + 2)AZD9833 300 mg (Stage 2)AZD9833 75 mg (Stage 3)AZD9833 150 mg (Stage 3)Total
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White3033133029135
More than one race000000
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AZD9833 75 mg (Stage 1 + 2)AZD9833 150 mg (Stage 1 + 2)AZD9833 300 mg (Stage 2)AZD9833 75 mg (Stage 3)AZD9833 150 mg (Stage 3)Total
Hispanic or Latino000459
Not Hispanic or Latino2932132624124
Other110002
08

Study locations

12 sites
  • Research Site
    Batumi, 6000, Georgia
  • Research Site
    Tbilisi, '0112, Georgia
  • Research Site
    Tbilisi, '0186, Georgia
  • Research Site
    Tbilisi, 0159, Georgia
  • Research Site
    Tbilisi, 0179, Georgia
  • Research Site
    Aguascalientes, 20230, Mexico
  • Research Site
    Mexico City, '14080, Mexico
  • Research Site
    Derby, DE22 3NE, United Kingdom
  • Research Site
    Leicester, LE1 5WW, United Kingdom
  • Research Site
    Liverpool, L7 8XP, United Kingdom
  • Research Site
    London, W12 0HS, United Kingdom
  • Research Site
    Manchester, M23 9LT, United Kingdom
09

References and documents

Publications

  • Robertson JFR, Gogitidze T, Katashvili Z, Rocha JEB, Arkania E, Moppett I, Cheung KL, Nemsadze G, Ajimi M, Klinowska T, Lindemann JPO, Mathewson A, Morrow CJ, Nikolaou M, Scaltriti M, Sykes A, Dzagnidze G. Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study. J Clin Oncol. 2026 Mar 20;44(9):750-761. doi: 10.1200/JCO-25-01548. Epub 2026 Jan 16. PubMed 41628308 ↗
  • Hamilton E, Oliveira M, Turner N, Garcia-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Ruiz-Borrego M, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird RD. A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. Ann Oncol. 2024 Aug;35(8):707-717. doi: 10.1016/j.annonc.2024.04.012. Epub 2024 May 8. PubMed 38729567 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jun 2023, 31 months.

Results were first posted in Jan 2025, 1 year 7 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 31 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2020
First posted
Oct 19, 2020
StartActual
Nov 2, 2020
Primary completionActual
Jun 19, 2023
CompletionActual
Jun 19, 2023
Results first posted
Jan 24, 2025
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04588298
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 19, 2020
Start date
Nov 2, 2020
Primary completion
Jun 19, 2023
Completion
Jun 19, 2023
Results posted
Jan 24, 2025
Last update
Jan 24, 2025

Study contacts

John Robertson
principal investigator · Graduate Entry Medicine & Health School, University of Nottingham, Royal Derby Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD9833

Start the discussion